Novartis Pharmaceuticals

Novartis Pharmaceuticals, the US clinical operations arm of the Swiss multinational Novartis AG, runs one of the most active clinical trial programs in the biopharmaceutical industry. The company's pipeline focuses heavily on oncology, gene and cell therapy, immunology, neuroscience, and cardiovascular disease. Novartis has pioneered several breakthrough therapies including imatinib (Gleevec) for CML — widely regarded as the first molecularly targeted cancer therapy — and tisagenlecleucel (Kymriah), the first FDA-approved CAR-T cell therapy.

In oncology, Novartis trials frequently evaluate novel combinations of targeted small molecules, radioligand therapies (a growing focus since the acquisition of Endocyte and the development of lutetium-177 PSMA therapy for prostate cancer), and immuno-oncology agents. The company's cardiovascular portfolio includes sacubitril/valsartan (Entresto) outcomes studies and multiple programs in heart failure with preserved ejection fraction. The rare disease and gene therapy program — centered on the Novartis Gene Therapies unit — includes zolgensma (for spinal muscular atrophy) and an expanding pipeline of one-time genetic treatments.

Novartis operates clinical research sites globally, with major trial concentrations in the United States, Germany, France, Spain, the United Kingdom, and Japan. Participants in Novartis trials are enrolled at academic hospitals, specialized cancer centers, and selected community practices. All eligibility criteria, site contact information, and consent documentation are available through ClinicalTrials.gov under the relevant NCT number.

Frequently Asked Questions — Novartis Pharmaceuticals